Scarica l'app Stockscreener
2.18
2.83%
0.06
Pre-mercato:
2.21
0.03
+1.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SAVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Cassava Sciences Inc Borsa (SAVA) Ultime notizie
Why Cassava Sciences Inc. Equity Warrant stock remains a top recommendationREITs Market Trends & Big Gains Small Capital - ulpravda.ru
2026 world cup star players odds: Why Cassava Sciences Inc. Equity Warrant stock remains undervalued2026 world cup usa national team round of 16 playmakers counter attacking expert forecast expert opinion - ulpravda.ru
Sector Leaders Rotate Capital Into VCU Data Management LimitedTop Performing Stocks & Free Significant Capital Appreciation - earlytimes.in
Aug Reactions: Will Cassava Sciences Inc stock reach all time highs in 2025Market Sentiment Review & Low Volatility Stock Suggestions - moha.gov.vn
Multi Factor Analysis Ranks Ekansh Concepts Limited as Strong BuyStock Price Targets & Register for the Next Free Workshop - earlytimes.in
Quarterly Earnings: Will Cassava Sciences Inc stock see insider buyingInsider Selling & Weekly Watchlist for Hot Stocks - moha.gov.vn
HALPER SADEH LLC ENCOURAGES CASSAVA SCIENCES, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - The Malaysian Reserve
Cassava Sciences settles securities class action for $31.25 million By Investing.com - Investing.com Australia
Cassava Sciences agrees to settle long-running investor lawsuit - The Business Journals
Cassava Sciences agrees to $31.25 million settlement in securities class action By Investing.com - Investing.com Nigeria
Cassava Sciences agrees to $31.25 million settlement in securities class action - Investing.com
Cassava Sciences Agrees to Pay $31.25 Million to Settle Securities Class Action - marketscreener.com
[8-K] CASSAVA SCIENCES INC Reports Material Event | SAVA SEC FilingForm 8-K - Stock Titan
Cassava settles securities class action suit (SAVA:NASDAQ) - Seeking Alpha
Cassava Sciences settles securities class action for $31.25 million - Investing.com
Cassava Sciences, Inc. Reaches $31.25 Million Settlement in Consolidated Securities Class Action Litigation - Quiver Quantitative
Cassava announces agreement to settle securities class action litigation - marketscreener.com
Cassava Announces Agreement to Settle Securities Class Action Litigation - GlobeNewswire
Cassava Sciences Shares Plunge After FDA Intervention - AD HOC NEWS
Published on: 2025-12-22 08:32:25 - Улправда
Can Cassava Sciences Inc. stock outperform in 2025 bull marketQuarterly Portfolio Report & Low Drawdown Momentum Trade Ideas - Улправда
Why Cassava Sciences Inc. Equity Warrant stock appeals to dividend seekersWeekly Earnings Recap & Reliable Price Breakout Alerts - Улправда
How Cassava Sciences Inc. stock responds to policy changesFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
Cassava Sciences (NASDAQ:SAVA) Stock Price Down 23.9%What's Next? - MarketBeat
Will Cassava Sciences Inc. stock benefit from sector rotationQuarterly Investment Review & Real-Time Stock Price Movement Reports - Улправда
Cassava Sciences stock on track for worst day in about 9 months — what’s driving today’s selloff? - MSN
Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Asianet Newsable
FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold - Benzinga
Cassava Sciences stock falls after FDA places clinical trial on hold By Investing.com - Investing.com South Africa
Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Australia
Cassava Sciences Shares Fall Pre-Bell After FDA Clinical Hold on Simufilam Trial - marketscreener.com
Cassava Sciences down on delay for epilepsy study (SAVA:NASDAQ) - Seeking Alpha
Rate Cut: How Cassava Sciences Inc. stock responds to policy changesEarnings Trend Report & AI Powered Market Trend Analysis - Улправда
Does Cassava Sciences Inc. Equity Warrant stock trade at a discount to peersDollar Strength & Entry Point Confirmation Signals - DonanımHaber
Is Cassava Sciences Inc. stock a dividend growth opportunityJuly 2025 Review & Community Driven Trade Alerts - DonanımHaber
Why Cassava Sciences Inc. Equity Warrant stock remains undervaluedPortfolio Performance Report & Weekly Return Optimization Plans - Улправда
Cassava Sciences IncOn Dec 15, FDA places full clinical hold on Cassava's trialSEC filing - marketscreener.com
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy By Investing.com - Investing.com South Africa
Cassava Sciences receives FDA clinical hold on simufilam trial for TSC epilepsy - Investing.com Nigeria
FDA Places Clinical Hold on Cassava’s Epilepsy Trial - TipRanks
Cassava Sciences Receives FDA Clinical Hold on Simufilam Trial - TradingView — Track All Markets
Published on: 2025-12-18 21:27:30 - Улправда
Cassava Sciences (NASDAQ: SAVA) details 2025 executive bonuses and simufilam TSC focus - Stock Titan
Cassava Sciences (SAVA) Stock Analysis Report | Financials & Insights - Benzinga
Cassava Sciences Submits IND Application for Simufilam - MSN
Cassava Sciences rises 10% after market close on CEO stock buy - MSN
Why Cassava Sciences Inc. Equity Warrant stock is rated strong buyDividend Hike & High Accuracy Investment Signals - Newser
Why Cassava Sciences Inc. (PX91) stock appeals to dividend investors2025 Geopolitical Influence & Free Technical Pattern Based Buy Signals - Newser
Why Cassava Sciences Inc. (PX91) stock could be next leader2025 Market Trends & Weekly Consistent Profit Watchlists - Newser
Can Cassava Sciences Inc. (PX91) stock deliver double digit returnsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):